hotspot -WSS

hotspot

author：explore 2025-09-03 05:24:57 - browse：459

The Johnson and Johnson booth at ESMO in Madrid. — The Johnson & Johnson booth at ESMO 2023. Andrew Joseph/STAT

MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson and AstraZeneca — to gain an edge in the market for targeted lung cancer treatments. A primetime presentation here Monday amounted to the latest salvo.

At the annual meeting of the European Society for Medical Oncology, J&J unveiled three studies of its drug Rybrevant in different patient groups with non-small cell lung cancer with EGFR mutations. All were successful, with the drug, sometimes used in combination with other therapies, helping stave off progression of the disease.

In an interview, Mark Wildgust, J&J’s vice president of global medical affairs for oncology, framed the totality of the research as a case that Rybrevant could become a regularly used treatment for these patients.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Pumping milk in bathrooms at health conferences is common

Wikipedia

WSS

Stem cell treatment guidelines are released by FDA

Crinetics acromegaly drug succeeds in late

Immunocompromised patients offer clues on chronic Covid

Trump surgeon general acknowledges mistakes during Covid

A rare thyroid diagnosis led to unexpected, all

Listen: Biogen's potential pivot, & Illumina's next chapter

leisure time

hotspot

explore

DIEP, the 'gold standard' of breast reconstruction, is under threat

Crinetics acromegaly drug succeeds in late

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA sets aggressive timeline for overhauling inspection procedures

Peter Hotez and the public health issue of online harassment

How generative AI is inspiring dreams of a health data revolution

Hollywood unions extend contract negotiations for actors

Stem cell treatment guidelines are released by FDA

Novavax promises a turnaround & Lilly roils the obesity market

NIH nominee Bertagnolli will get October confirmation hearing

hotspot

A new House health package & hospitals’ new site

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Weighted lottery helped low

High breast density mammograms need follow

How generative AI is inspiring dreams of a health data revolution

Advances in CAR

Wikipedia

knowledge

focus

leisure time